If your child’s bedwetting hasn’t responded to first-line measures, or if a GP or enuresis clinic is involved, medication will likely come up. The British National Formulary (BNF) is the reference clinicians use when prescribing — and understanding what it lists for nocturnal enuresis, what those options actually do, and when each is appropriate gives you a clearer foundation for those conversations.
This article covers the prescribing options for nocturnal enuresis as recognised in the BNF, without recommending any specific course of action. Prescribing decisions belong with the clinician who knows your child.
What Is the BNF and Why Does It Matter?
The British National Formulary is a joint publication of the British Medical Association and the Royal Pharmaceutical Society, updated regularly and used by prescribers across the NHS. It sets out licensed indications, dosing guidance, cautions, contraindications and monitoring requirements for medicines used in the UK.
When a GP, paediatrician or continence nurse considers medication for nocturnal enuresis, the BNF is their clinical reference. Knowing which drugs appear there — and what the BNF says about them — helps parents engage more confidently with prescribers and understand why one option might be offered rather than another.
Desmopressin (DDAVP)
Desmopressin is the most commonly prescribed medication for nocturnal enuresis in the UK and is the first-line pharmacological option recommended in NICE guidance (CG111). It is a synthetic analogue of antidiuretic hormone (ADH), which normally signals the kidneys to concentrate urine at night. Children who wet the bed often produce insufficient ADH during sleep, resulting in more urine than the bladder can hold.
How it is used
The BNF lists desmopressin for the treatment of primary nocturnal enuresis in children aged five and over. It is available as:
- Oral tablets (desmopressin acetate, 200 micrograms, with dose titration to 400 micrograms if needed)
- Sublingual melt formulations (120–240 micrograms), which avoid first-pass metabolism and may be preferred for ease of administration
It is taken shortly before bedtime. Fluid intake must be restricted for one hour before and eight hours after administration — this is a firm clinical requirement, not a suggestion, as overhydration can cause hyponatraemia (dangerously low sodium levels).
Effectiveness and limitations
Desmopressin works well for many children but does not address the underlying cause. It reduces urine production that night; it does not train the bladder or alter sleep arousal. When it is stopped, wetting typically returns unless a gradual withdrawal protocol is used. Some families find it invaluable for managing specific periods — school trips, sleepovers, holidays — even if it isn’t used every night.
If desmopressin has been partly effective but wet nights persist, or if it worked initially but has become less effective over time, there are structured next steps worth discussing with a prescriber. The posts Desmopressin Is Partly Working But There Are Still Wet Nights: What to Add and Desmopressin Has Stopped Working After Six Months: What Comes Next cover those scenarios in detail.
Enuresis Alarms: Not a Drug, But BNF-Adjacent
The BNF does not prescribe enuresis alarms — these are devices, not medicines — but NICE guidance (CG111) positions the alarm as the preferred first-line treatment for motivated children over five where appropriate. Alarms are listed in the Drug Tariff and can be prescribed on FP10 in England.
They work by conditioning: the alarm triggers at the first sign of wetness, gradually training the child to wake (or inhibit voiding) before wetting occurs. Success requires commitment from both the child and the family, typically over a minimum of eight to twelve weeks.
Alarm treatment is often combined with desmopressin in children who haven’t responded to either alone. If you’re navigating alarm difficulties, We Have Used the Bedwetting Alarm for Eight Weeks and Nothing Has Changed addresses what to consider next.
Oxybutynin
Oxybutynin is an antimuscarinic drug primarily used for overactive bladder. It is not a first-line treatment for primary nocturnal enuresis, but the BNF does reference its use in children with enuresis associated with bladder overactivity or daytime urgency symptoms.
In practice, it may be prescribed where there is evidence of reduced functional bladder capacity contributing to nighttime wetting, or where daytime wetting is also present. It works by reducing bladder contractions. Side effects include dry mouth, constipation, flushing and blurred vision.
Oxybutynin is more typically initiated at a specialist level — paediatric urology or a continence clinic — rather than in primary care.
Amitriptyline
Amitriptyline is a tricyclic antidepressant that also appears in BNF guidance for nocturnal enuresis. It is not a first-line or commonly used option — NICE guidance notes that it should only be considered when other treatments have failed, with close clinical supervision, given its side effect and overdose risk profile.
The mechanism by which amitriptyline reduces bedwetting is not fully understood. It may act on sleep architecture, bladder muscle, or ADH regulation. It carries a significant caution in prescribing practice: the therapeutic margin is narrow, accidental ingestion by younger siblings is a serious risk, and it requires ECG monitoring in some contexts.
Most clinicians will exhaust desmopressin and alarm-based approaches — and combination therapy — before considering amitriptyline. If you’ve reached this stage, you are almost certainly under specialist care.
Combination Therapy
Where neither desmopressin nor the alarm has achieved dryness independently, NICE guidance supports combining both approaches. The BNF does not explicitly list combinations, but prescribers working within NICE CG111 are familiar with the evidence base.
Combination approaches require coordination — typically through an enuresis clinic or paediatrician — and careful monitoring. If your child has been discharged from a clinic without achieving dryness, the post My Child Has Been to the Bedwetting Clinic and Was Discharged Without Being Dry sets out what options remain and how to escalate if needed.
What the BNF Does Not Cover
The BNF deals only with licensed medicines and their clinical use. It does not address:
- Bedwetting products — pull-ups, nappies, bed pads, mattress protectors
- Fluid management strategies
- Behavioural approaches such as reward charts or bladder training
- The emotional impact on children and families
For many families, especially those managing ongoing or treatment-resistant wetting, the practical question of containment runs in parallel with any medical treatment. Medication reduces wetting frequency; it rarely eliminates it entirely, and reliable overnight protection remains relevant throughout.
Getting Access to Prescribing Options
In England, initial prescribing for nocturnal enuresis typically sits with the GP, school nurse or community enuresis service. If first-line options have been exhausted, referral to a paediatric continence team or community paediatrician is appropriate — and in many areas it can be requested directly.
If you have encountered resistance from a GP in accessing treatment, The GP Said Just Wait and See But My Child Is Ten: What to Say to Get a Referral provides specific language and escalation routes.
NICE CG111 (updated 2010, partially reviewed since) remains the governing clinical guideline. It is publicly available and can be cited in GP consultations. Knowing that guidelines exist — and that they support active treatment from age five — gives parents a clearer basis for those conversations.
A Practical Summary
- Desmopressin — first-line pharmacological option; reduces overnight urine production; short-term or structured use; fluid restriction essential
- Enuresis alarm — preferred behavioural/device intervention; prescribable on the Drug Tariff; requires commitment over eight to twelve weeks
- Oxybutynin — for associated overactivity or daytime symptoms; typically specialist-initiated
- Amitriptyline — third-line only; significant cautions; specialist supervision required
- Combination desmopressin + alarm — evidence-based second-tier approach where monotherapy has failed
Understanding what the BNF lists for nocturnal enuresis — and how those options fit within NICE guidance — means you can enter prescribing conversations with a clear picture of what exists, what’s typically considered when, and what questions are worth asking. If your child’s wetting has proved difficult to manage despite treatment, that conversation deserves to happen with someone who can review the full clinical picture.
